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Amino acids are fundamental nutrients required for protein synthesis. The branched chain amino acids (BCAAs) leucine, isoleu-
cine, and valine are the most abundant of the essential amino acids. BCAAs have recently been recognized as having functions in 
processes other than simple nutrition. For example, metabolic diseases are characterized by higher levels of circulating BCAAs. 
Moreover, supplementation with or deficiency in BCAAs is closely related to the regulation of metabolic homeostasis. Indeed, 
leucine deprivation induces increased lipolysis and thermogenesis, which result in fat loss, as well as suppressed lipogenesis and 
enhanced insulin sensitivity in the liver. Accumulating evidence has indicated that several amino acid sensors, including GCN2, 
ATF4, mTOR, and AMPK, play pivotal roles in the regulation of lipid metabolism, glucose metabolism, and energy homeostasis. 
Furthermore, the hypothalamus is critical for sensing amino acid levels and mediates the metabolic adaptation of the body upon 
limitation of essential amino acids (EAAs) through regulating expression of the S6K1, MC4R, and CRH. In this review, we high-
light recent studies investigating the cellular mechanisms linking amino acids, amino acid sensors, metabolic regulation, and 
metabolic diseases. Amino acid sensing and metabolic regulation have become research hotspots in the metabolic field.  
branched chain amino acids, amino acid sensor, lipid metabolism, glucose metabolism, energy homeostasis, obesity,  
diabetes 
 




Metabolic diseases, including obesity, fatty liver, and dia-
betes, have become a major public health problem, and their 
prevalence has increased dramatically over the last few 
decades among all ages worldwide. The obesity epidemic 
has been recognized by the World Health Organization 
(WHO) as one of the top 10 global health problems. Obesity 
has reached epidemic proportions in many countries around 
the world and is strongly linked to a number of chronic dis-
eases, including diabetes, hypertension, and cardiovascular 
disease. Worldwide, more than 1 billion adults are over-
weight and over 300 million are obese [1]. Data on the 
prevalence of diabetes by age and sex from all 191 WHO 
member states revealed that the estimated prevalence of 
diabetes for all age groups worldwide was 2.8% in 2000 and 
is expected to increase to 4.4% by 2030. The total number 
of people with diabetes is projected to rise from 171 million 
in 2000 to 366 million in 2030 [2].    
In China, the rapid transformation from a rural agrarian 
society to an industrial society with increased wealth has 
impacted the health of the entire population, especially evi-
dent by the increasing high prevalence of metabolic diseases. 
Obesity, especially abdominal obesity, contributes to many 
metabolic disorders, including metabolic syndrome (MetS), 
type 2 diabetes (T2DM), and cardiovascular diseases 
(CVDs). In China, more than one-third of adults are over-
weight or obese and 10%–20% of all adults are affected by 
MetS [3]. The rapid growth of the overweight/obese popu-
lation in China will undoubtedly raise the worldwide preva-
lence of chronic disease. Indeed, diabetes has reached epi-
demic proportions in the general adult population in China. 
Overall, 92.4 million adults 20 years of age or older (9.7% 
of the adult population) have diabetes, and 60.7% of these 
cases remain undiagnosed [4]. Fatty liver (steatosis) is 
highly prevalent in China and is often linked to obesity. The 
community prevalence of non-alcoholic fatty liver disease 
(NAFLD) is approximately 15%, and the prevalence of 
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NAFLD has doubled in the past decade [5]. Metabolic dis-
eases, including obesity, fatty liver, and diabetes have be-
come a major public health problem in China, and strategies 
aimed at the prevention and treatment of such conditions are 
needed. Moreover, the relative contribution of nutrition- 
related chronic diseases to the total disease burden of the 
society and health care costs has risen continuously over the 
last few decades. Although a number of pharmacological 
approaches have been investigated in recent years, few safe, 
therapeutically effective products have been developed. 
Thus, there is an urgent need to better exploit the potential 
of disease prevention via dietary changes.  
Amino acids are fundamental nutrients required for pro-
tein synthesis. Twenty amino acids, termed proteinogenic or 
standard amino acids, are naturally incorporated into poly-
peptides. Among them, the branched chain amino acids 
(BCAAs) leucine, isoleucine, and valine are the most abun-
dant of the essential amino acids (EAAs) and cannot be cre-
ated from other compounds by the human body; therefore, 
they must be ingested in the form of food. Amino acids are 
important in nutrition and are commonly used in nutritional 
supplements, fertilizers, food technology, and in the indus-
try. Recently, accumulating evidence has indicated that 
BCAAs have essential roles in the physiological regulation 
of many processes besides simple nutrition. In this review, 
we will provide an overview on the function of BCAAs in 
the regulation of metabolic processes in the body, including 
lipid metabolism, glucose metabolism, and energy homeo-
stasis, and the effects of these BCAAs on the development 
of metabolic disease. 
1  Amino acids and obesity 
Obesity is a condition associated with the accumulation of 
excessive body fat resulting from chronic imbalance of 
abundant energy intake and low energy expenditure [6]. 
Various strategies have been proposed to treat obesity by 
promoting fat mobilization, increasing energy expenditure, 
and/or reducing food intake [1,7]. Accumulating evidence 
has shown that diets with higher protein and reduced car-
bohydrates are beneficial for weight loss and increase loss 
of body fat [8–10]. Because leucine can interact with the 
insulin-signaling pathway and appears to regulate the oxida-
tive use of glucose by skeletal muscle through stimulation 
of glucose recycling via the glucose-alanine cycle, the key 
to understanding the relationship between dietary protein 
and carbohydrates is the relationship between the intake of 
leucine and glucose [11].  
It has long been recognized that several amino acids, in-
cluding BCAAs, are elevated in the blood of obese subjects 
relative to healthy individuals [12]. In 2009, to gain a 
broader understanding of the metabolic and physiological 
differences between obese and lean subjects, Newgard et al. 
[13] applied comprehensive metabolic profiling tools to 
compare the metabolic profiles of obese versus lean humans; 
their data revealed that increased catabolism of BCAAs 
correlated with obesity. This was the first direct report 
demonstrating the relationship between BCAAs and meta-
bolic signatures in the serum of obese individuals. Zhang et 
al. [14] demonstrated that doubling the intake of dietary 
leucine without increasing food intake decreased adiposity 
by 25% (P < 0.01) in mice fed a high-fat diet (HFD); this 
change was a result of increased resting energy expenditure 
associated with increased expression of uncoupling protein 
3 in brown and white adipose tissue (BAT and WAT, re-
spectively) and in skeletal muscle [14]. The effect of in-
creasing dietary leucine, however, is still controversial. Ad-
ditional studies have shown that dietary supplementation of 
leucine has no effect on lipid metabolism [15]. In contrast, 
Guo et al. [16] found that mice maintained on a leu-
cine-deficient diet for 7 d experienced a dramatic reduction 
in abdominal fat mass and differential lipid metabolism in 
the liver, which was the first report of the effects of leucine 
deprivation on lipid metabolism and was significant enough 
to be highlighted in Nature Medicine. 
Food intake determines energy intake, which plays a key 
role in the development of obesity. Recently, increased hy-
pothalamic availability of the BCAA leucine was shown to 
act as a potent signal for reducing food intake [17]. Addi-
tionally, supplementation of an HFD with BCAAs 
(HF/BCAA) reduces food intake and body weight [13]. In 
contrast, our research work indicated that leucine depriva-
tion for 7 d resulted in a 15% reduction in food intake and 
body weight and an approximately 50% reduction in ab-
dominal fat compared with those in mice maintained on a 
control diet [18]. Furthermore, 1.1 μg leucine in 1.0 μL PBS 
administered by intravenous injection once a day for 7 d did 
not influence food intake, but modestly blocked body 
weight reduction in mice maintained on a leucine-deficient 
diet [19]. In addition to many identified hypothalamic 
pathways controlling food intake [20], these results sug-
gested that leucine deprivation induces decreased food in-
take and that leucine also is a key hypothalamic regulator of 
food intake in mice.  
Enhanced lipid mobilization is an effective method for 
reducing fat. In contrast with work demonstrating that the 
addition of leucine improves insulin sensitivity and the 
downregulation of hepatic glucose-6-phosphatase [14], 
Guo’s research further showed that leucine deprivation ac-
celerates triglyceride lipolysis and β-oxidation gene expres-
sion in WAT. In a study that was the first to demonstrate the 
relationship between leucine and metabolism, researchers 
showed that the levels of phosphorylated HSL (p-HSL) and 
mRNAs encoding the transcription factor peroxisome pro-
liferator-activated receptor α and its target genes carnitine 
palmitoyltransferase 1 (Cpt1) and fatty acyl-CoA oxidase 
(Aco) significantly increased in the WAT of leu-
cine-deprived mice [18]. Moreover, lipogenic genes, in-
cluding acetyl CoA carboxylase 1 (Acc1), fatty acid syn-
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thase (Fas), and stearoyl CoA desaturase (Scd)-1, are all 
suppressed in the WAT of mice fed a leucine-deficient diet 
for 7 d [18]. 
BAT plays a pivotal role in the prevention or treatment 
of obesity, and the identification of BAT in adult humans 
was reported in 2009 [21]. Interestingly, elimination of leu-
cine from the diet can significantly increase energy ex-
penditure, which mainly contributes by increasing thermo-
genesis due to upregulation of UCP1 expression in BAT. 
Additionally, leucine deprivation activates the expression of 
Adrb3, the main β-adrenoceptor isoform in BAT and WAT, 
which suggests that the sympathetic nervous system is in-
volved in the regulation of leucine deprivation-induced fat 
loss [18]. Although the mechanisms underlying the leucine 
deprivation-induced regulation of thermogenesis are largely 
unclear, models incorporating use of leucine-deficient diets 
give new insight into the dietary prevention of obesity. 
Guo’s group also demonstrated that, in addition to leu-
cine, isoleucine- or valine-deficient diets could also induce 
significant fat loss due to enhanced lipid mobilization and 
increased energy expenditure [22]. Subsequently, a question 
arises regarding how BCAA deprivation induces fat loss 
with increased energy expenditure. In a previous report, 
knockout of the BCATm gene, encoding the enzyme cata-
lyzing the first step in peripheral BCAA metabolism, re-
sulted in decreased adiposity and body weight along with 
increased energy expenditure and protection from diet-  
induced obesity in mice. Increased energy expenditure was 
strongly associated with food consumption and an active 
futile cycle of increased protein degradation and synthesis 
[23]. These results suggest that BCAA metabolism is close-
ly related to protein metabolism and the regulation of ener-
gy homeostasis. 
2  Amino acids and diabetes 
Several amino acids, including BCAAs, have long been 
known to be elevated in the blood of patients with insu-
lin-resistance or type 2 diabetes relative to healthy control 
individuals [12]. In 2009, Newgard et al. [13] applied com-
prehensive metabolic profiling tools to reveal that increased 
catabolism of BCAA was correlated with insulin resistance. 
Recently, Wang et al. [24] reported that isoleucine, leucine, 
valine, tyrosine, and phenylalanine had highly significant 
associations with future diabetes. This evidence suggests 
that amino acids, especially BCAAs, are potentially im-
portant biomarkers for the diagnosis of diabetes and predi-
abetes. 
However, this is inconsistent with the fact that supple-
mentation with or deletion of amino acids affects insulin 
sensitivity. Interestingly, nutritional supplementation with a 
special mixture of oral amino acids also significantly im-
proves insulin sensitivity in elderly subjects with type 2 
diabetes [4]. In addition, supplementation with BCAAs has 
the potential to improve glucose metabolism in patients with 
liver cirrhosis [25]. BCAAs, especially leucine, are closely 
related to glucose metabolism and insulin sensitivity both in 
vivo and in vitro. Zhang and colleagues [14] recently 
demonstrated that increased oral intake of leucine improves 
whole-body insulin sensitivity, decreases plasma concentra-
tions of glucagon and glucogenic amino acids, and down-
regulates hepatic glucose-6-phosphatase in mice maintained 
on an HFD. However, the effect of increasing dietary leu-
cine remains controversial. Some reports have shown that 
increased serum levels of leucine have no effect on insulin 
sensitivity [15], while others have shown that increase se-
rum leucine promotes insulin resistance in humans and an-
imal models of obesity [13,26]. In contrast, dietary leucine 
deprivation decreases serum insulin levels 3-fold in mice 
with normal glucose levels, suggesting that increased insu-
lin sensitivity may occur in response to leucine deprivation 
[16]. Further work has shown that leucine deprivation im-
proves hepatic insulin sensitivity by sequentially activating 
general control nonderepressible 2 (GCN2) and decreasing 
mammalian target of rapamycin (mTOR) signaling, as well 
as activating AMP-activated protein kinase (AMPK) in the 
context of leucine deprivation [27]. Moreover, leucine dep-
rivation also improves insulin sensitivity in nutritionally or 
genetically induced insulin resistance models, which pro-
vides hope to patients with diabetes. 
Through analyzing amino acid levels in the serum of leu-
cine-deprived mice, Guo’s group found that these mice dis-
played decreased leucine, but increased isoleucine and va-
line in the serum. Because the levels of all 3 of these 
BCAAs, as well as other amino acids, are elevated in insu-
lin-resistant conditions in vivo [13,26] and in vitro [28], the 
low level of leucine may play a key role in promoting en-
hanced insulin sensitivity in mice fed a leucine-deficient 
diet. Unpublished data from our laboratory suggest that iso-
leucine or valine deprivation also improves insulin sensitiv-
ity via a different mechanism. 
Although leucine is recognized as an important nutrient 
regulator involved in metabolic processes, the mechanisms 
through which leucine signaling or BCAA metabolism is 
related to the regulation of insulin sensitivity and glucose 
metabolism have not yet been elucidated. Recently, Higuchi 
et al. [29] indicated that BCAA administration enhanced the 
mRNA expression of L-Gk, Srebp-1c, Lxr, and Chrebp 
and suppressed the expression of G6pase mRNA in the rat 
liver without affecting glycogen synthase expression or se-
rum glucose concentrations. These results suggest that 
BCAA metabolism is closely related to insulin sensitivity 
and glucose metabolism. However, it is currently unclear 
how amino acid-stimulated signal transduction pathways 
affect insulin sensitivity. One hypothesis is that the amino 
acid transporter plays a critical role in this process, which 
has been illustrated in a previous study [30]. Another possi-
bility is that enzymes catalyzing steps in peripheral BCAA 
metabolism mediate amino acid-regulated insulin sensitivity 
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or glucose homeostasis. For example, it was previously re-
ported that knockout of the BCATm gene in mice resulted in 
marked improvement in glucose and insulin tolerance [23]. 
3  Amino acid sensors and metabolic diseases 
Amino acid sensing is a critical process that enables cells to 
respond properly to changes in amino acids levels in order 
to maintain metabolic homeostasis. Amino acid sensors or 
transporters play key roles in these processes. Great pro-
gress has been made in studying the mechanisms underlying 
amino acid sensing in unicellular organisms, i.e., yeast and 
Escherichia coli. However, it is still unclear how the body 
senses amino acids levels to control metabolic homeostasis, 
including lipid metabolism, glucose metabolism, and energy 
homeostasis.  
Currently, amino acid sensing and metabolic regulation 
have become a research hotspot in the metabolic field. Be-
sides focusing on the effects of EAAs on metabolic regula-
tion, Guo’s laboratory is also interested in exploring novel 
functions of certain proteins implicated in amino acid regu-
latory pathways, including GCN2, ATF4, mTOR, AMPK, 
etc (Figure 1). 
3.1  GCN2 
GCN2 is recognized as a sensor for amino acid deprivation. 
As a kinase, GCN2 is activated by uncharged tRNAs in 
response to the deprivation of EAAs in yeast and mammals 
[31]. Activated GCN2 phosphorylates eukaryotic initiation 
factor 2-α (eIF2α), resulting in the repression of general 
protein synthesis and increased translation of proteins re-
lated to amino acid biosynthesis and transport [32]. In 2007, 
Guo identified a novel function of GCN2 in regulating lipid 
metabolism during leucine deprivation. Knockout of the 
Gcn2 gene in mice results in fatty liver, mediated by high 
expression of FAS, when the animals are fed a leu-
cine-deficient diet for 7 d [16] and results in insulin re-
sistance following leucine deprivation [27]. Furthermore, 
Xiao et al. [27] found that GCN2 also plays a critical role in 
the regulation of insulin sensitivity and glucose metabolism 
via the mTOR pathway. Taken together, these results 
strongly suggest that GCN2 is a novel regulator of lipid and 
glucose metabolic adaptation to deprivation of EAAs. It is a 
key linker between amino acids, lipids, and glucose metab-
olism. Further investigations into the mechanisms underly-
ing the activation of GCN2 by leucine deprivation in the 
liver are required. 
3.2  ATF4 
Activating transcription factor 4 (ATF4), also known as 
CREB2 and C/ATF, belongs to the family of basic zipper- 
containing proteins [33,34]. In mammals, the GCN2/ATF4 
pathway has been recognized as the main pathway involved 
in the regulation of gene expression in response to amino 
acid deprivation [35–37]. GCN2-dependent phosphorylation 
of eIF2α increases in response to the presence of uORF in 
its 5′ untranslated region (UTR), promoting amino acid bi-
osynthesis and transport upon amino acid deprivation [38]. 
In addition, accumulating evidence suggests that ATF4 
plays an important role in the regulation of the high level of 
proliferation required during fetal-liver hematopoiesis [39], 
long-term memory [40], osteoblast differentiation [41], ER 
stress [42,43], glucose metabolism, and energy homeostasis 
[44]. With respect to the regulation of glucose metabolism 
by ATF4, Seo et al. [44] first reported that Atf4-null mice 
are hypoglycemic, indicating that ATF4 regulates mamma-
lian carbohydrate metabolism and that the Atf4 mutation 
abrogates diet-induced diabetes as well as hyperlipidemia 
and hepatosteatosis. All of these Atf4 mutant phenotypes are 
related to the activation of the mTOR pathway [44]. Anoth-
er study indicated that ATF4 inhibits insulin secretion and 
decreases insulin sensitivity through its osteoblastic expres-
sion in the liver, fat, and muscle [45]. Recently, Kode et al.   
 
 
Figure 1  Amino acid sensors and metabolic regulation. 
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[46] demonstrated that FoxO1 colocalizes with ATF4 in the 
osteoblast nucleus and that FOXO1 and ATF4 cooperate in 
osteoblasts to increase glucose levels and decrease glucose 
tolerance. All of these results suggested that ATF4 is a nov-
el regulator of glucose metabolism; however, much is still 
unknown, and the related mechanisms require further inves-
tigation. 
A recent study in Guo’s laboratory has led to the identi-
fication of a novel function for ATF4 in regulating lipid 
metabolism, thermogenesis, and glucose metabolism [47, 
48]. Atf4-deficient mice were found to be lean and exhibit 
increased energy expenditure due to increased thermogene-
sis in BAT, as described by Seo et al. [44], as well as in-
creased lipolysis and decreased lipogenesis in WAT [47]. 
When fed on a high-carbohydrate diet (HCD), ATF4-   
deficient mice became resistant to HCD-induced accumula-
tion of triacylglycerols (TAGs) in the liver, and impairment 
in glucose tolerance via suppression of HCD-induced stea-
royl-CoA desaturase 1 (SCD1) expression [48]. Considering 
of the higher body temperature of ATF4-deficient mice 
compare to wild-type mice [47], the physiological functions 
of ATF4 in response to cold stress were also investigated by 
Wang et al. The results showed that ATF4 is a negative 
regulator of PGC1α expression through competitive binding 
with cAMP response element-binding protein (CREB) at a 
cAMP response element site in the PGC1α promoter [49]. 
Because ATF4 is constitutively expressed in a wide variety 
of tissues, including the brain, heart, WAT, BAT, liver, 
lungs, and kidneys, we speculated that ATF4 plays a critical 
role in metabolic regulation. Further investigations are war-
ranted in this regard.  
3.3  mTOR 
mTOR is a serine/threonine protein kinase that has been 
shown to be essential for cell growth, protein synthesis, cell 
development, and cell proliferation [17,50,51]. mTOR 
forms 2 distinct complexes, mTOR complex 1 (mTORC1) 
and mTOR complex 2 (mTORC2). Studies have shown that 
mTORC1 is regulated by BCAA availability, especially 
leucine [52]. Intracerebroventricular injection of leucine can 
active mTOR in the hypothalamus, which is involved in the 
regulation of food intake [17]. In contrast, leucine depriva-
tion suppresses the activity of mTOR in the livers of mice.  
Moreover, accumulating evidence has indicated that ac-
tivation of mTOR/S6 kinase 1 (S6K1) signaling contributes 
to the development of insulin resistance. The mTOR down-
stream target S6K1 directly phosphorylates insulin receptor 
substrate 1 (IRS1) serine residues, including Ser-302/307 
[53], Ser-307/312 [54], Ser-632/636 [55], and Ser-1097/Ser- 
1101 [56], which results in the reduced activity of IRS1, 
thereby impairing PI3K/AKT signaling and increasing insu-
lin resistance [57,58]. As a specific inhibitor of mTORC1, 
rapamycin can reverse the effects of mTOR/S6K1 activa-
tion on insulin resistance [54]. On the other hand, S6K1- 
null mice exhibit reduced phosphorylation of IRS1 at Ser- 
636 and are resistant to diet-induced insulin resistance [59]. 
Additional studies have also shown that decreased mTOR/ 
S6K1 signaling increases insulin sensitivity [59,60]. Con-
sistent with these results, our research work had shown that 
leucine deprivation increases insulin sensitivity via sup-
pressing mTOR activity. Furthermore, overexpression of 
S6K1 reverses the effects of leucine deprivation on insulin 
sensitivity in a GCN2-dependent manner [27]. Thus, to-
gether with our results, these recent studies have suggested 
that mTOR acts as a sensor of leucine deficiency down-
stream of GCN2, thereby regulating insulin sensitivity. 
3.4  AMPK 
AMPK is a crucial cellular energy sensor and signal trans-
ducer for maintaining energy homeostasis, a process that is 
regulated by a wide array of metabolic stresses [61,62]. Re-
cent studies indicate that AMPK also plays a role in the 
regulation of insulin sensitivity by directly phosphorylating 
IRS1 [63] or by phosphorylating TSC2, an upstream inhibi-
tor of mTOR [64]. Stimulation of AMPK in skeletal muscle 
and liver is seen as an exciting prospect for the treatment of 
type 2 diabetes. AMPK activators, including metformin and 
rosiglitazone, increase insulin sensitivity and are used clini-
cally in the treatment of type 2 diabetes [65]. Moreover, 
AMPK has been shown to regulate insulin sensitivity and 
can be indirectly controlled by nutrient availability [66,67]. 
Indeed, leucine deprivation actives AMPK, contributing to 
the leucine deprivation-induced increase in insulin sensitiv-
ity [27]. In addition, AMPK activity is closely related to 
amino acid-stimulated insulin secretion [68]. These results 
indicate that AMPK also acts as a sensor for amino acids. 
Although it is not known how leucine deprivation activates 
AMPK, these studies provide new insights into the func-
tions of AMPK in nutritional regulation.  
4  Sensing of amino acids deficiency in the cen-
tral nervous system (CNS) 
Amino acid sensing occurs in the gastrointestinal tract, 
muscle, liver, brain, and other organs. Dysregulation of 
amino acid sensing induces protein metabolic diseases, 
metabolic diseases, or cancer. In this review, we focus on 
the sensing of EAA deficiency in the CNS in the context of 
metabolic diseases. In the classical behavioral test for EAA 
deficiency, animals detect and reject a diet lacking an EAA 
[69]. Indeed, animals detect and reject their first EAA-  
deficient meal within 20 min [70]. Lesion studies have 
shown that an intact anterior piriform cortex (APC) is es-
sential for the detection of EAA deficiency in vivo [71]. 
Further studies have shown that uncharged tRNA is the 
primary biochemical sensor of EAA deficiency in the APC 
and that GCN2 is activated in this process [72].  
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In 2006, Cota et al. [17] found that leucine actives 
mTOR in the hypothalamus to regulate food intake in rats. 
It is well established that the hypothalamus plays an im-
portant role in regulating energy homeostasis and lipid me-
tabolism [73–75]. Energy homeostasis is maintained by a 
balance between energy intake and energy expenditure. The 
hypothalamus has been shown to play a critical role in the 
regulation of these events by sensing changes in the con-
centrations of nutrients and hormones and coordinating 
subsequent physiological responses [20,76,77].  
Considering the comprehensive effects of leucine depri-
vation on energy homeostasis, lipid metabolism, and glu-
cose metabolism, Guo’s group investigated the possible 
involvement of the hypothalamus in regulating these pro-
cesses. They found that intracerebroventricular administra-
tion of leucine significantly attenuated abdominal fat loss 
via blocking the activation of hormone-sensitive lipase in 
the WAT and induction of UCP1 in the BAT in leucine-  
deprived mice. Furthermore, leucine deprivation was found 
to increase the expression of corticotrophin-releasing hor-
mone (CRH) in the hypothalamus via activation of the 
stimulatory G protein/cAMP/protein kinase A/CREB path-
way. Finally, the sympathetic nervous system was found to 
mediate the effect of leucine deprivation on fat loss. These 
results suggest that hypothalamic CRH is a critical sensor 
and transporter for stimulating fat loss upon leucine depri-
vation [19]. To further elucidate the molecular mechanisms 
underlying hypothalamic CRH regulation of leucine depri-
vation-stimulated fat loss, Guo’s group used intracerebro-
ventricular injection of adenoviral vectors to identify a nov-
el role for hypothalamic p70 S6K1, a major downstream 
effector of the leucine-deprivation sensing kinase mTOR, in 
the stimulation of energy expenditure by leucine deprivation. 
These studies showed that hypothalamic S6K1 modulates 
CRH expression in a melanocortin-4 receptor-dependent 
manner [78]. Taken together, Guo’s studies provide a new 
perspective for understanding the regulation of energy ex-
penditure by the hypothalamus and the importance of cross- 
talk between nutritional control and endocrine signal regu-
lation (Figure 2). Whether the hypothalamus senses other 
amino acids in a manner similar to that for leucine is un-
known, and further studies are required to completely elu-
cidate the mechanisms involved.  
5  Conclusion 
In summary, amino acids are novel regulators of nutrition 
and other metabolic processes and are closely involved in 
metabolic regulation and the development of metabolic dis-
eases. In these processes, several amino acid sensors, in-
cluding GCN2, ATF4, mTOR, and AMPK, play pivotal 
roles in the regulation of lipid metabolism, glucose metabo-
lism, and energy homeostasis. In addition, the hypothalamus, 
as a core center for metabolic regulation, is also critical for  
 
Figure 2  Amino acid sensing in hypothalamus and metabolic regulation. 
sensing amino acid levels and mediates the metabolic adap-
tation of the body upon limitation of EAAs. Although more 
clinical tests are required to confirm the safety of short- and 
long-term leucine deprivation and to determine the optimal 
concentration of leucine in humans, leucine-deficient diets 
have potential applications in the prevention or treatment of 
obesity, diabetes, and fatty liver. GCN2, ATF4, mTOR, and 
AMPK may also be new drug targets for metabolic disease. 
At present, amino acid sensing in metabolic regulation has 
become a research hotspot in the metabolic field. From this 
review, we hope to have presented topics that will be the 
subject of additional discussion in the future. 
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